PT - JOURNAL ARTICLE AU - Callahan, Cody J AU - Lee, Rose AU - Zulauf, Katelyn E. AU - Tamburello, Lauren AU - Smith, Kenneth P. AU - Previtera, Joe AU - Cheng, Annie AU - Green, Alex AU - Azim, Ahmed Abdul AU - Yano, Amanda AU - Doraiswami, Nancy AU - Kirby, James E. AU - Arnaout, Ramy TI - Rapid Open Development and Clinical Validation of Multiple New 3D-Printed Nasopharyngeal Swabs in Response to the COVID-19 Pandemic AID - 10.1101/2020.04.14.20065094 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.14.20065094 4099 - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065094.short 4100 - http://medrxiv.org/content/early/2020/04/17/2020.04.14.20065094.full AB - Background The SARS-CoV-2 pandemic has caused a severe international shortage of the nasopharyngeal (NP) swabs required for testing. We participated in an unprecedentedly open and urgent iterative process to help develop and validate new swabs.Methods We tested prototypes for material suitability, collection sufficiency, PCR compatibility, and the likelihood that they could be mass-produced, individually packaged, and sterilized quickly.Suitable prototypes were selected for an ongoing IRB-approved clinical trial. Participants were outpatients suspected of COVID-19 who presented to our drive-through test station. Each participant was swabbed with a control swab followed by a prototype swab. For each prototype, at least 10 control-swab positive and 10 control-swab negative PCR results were collected. We measured concordance using Cohen’s kappa, compared Ct values by Mann-Whitney U, and assessed staff preferences via written survey.Results We evaluated 45 materials and 150 designs from 23 individuals, laboratories, and companies. We have selected four so far for the clinical trial. Three have completed testing. For these, we obtained PCR results from control and prototype swabs from 230 people (74-79 pairs/prototype). Concordance was 0.85-0.89 on 10-19 control-swab positives and 58-67 control-swab negatives. Ct values were statistically indistinguishable from controls. Staff preferred two of the prototypes over the third but ultimately preferred the control swab most. The time elapsed between identification of the problem and development of a high-manufacturing-volume solution was three weeks.Conclusions Our experience provides lessons for how an open process can efficiently and effectively contribute to resolving a medical manufacturing crisis during a major pandemic.Trial registration number Beth Israel Deaconess Medical Center (BIDMC) Institutional Review Board (IRB) Protocol 2020P000323Competing Interest StatementThe authors have declared no competing interest.Clinical TrialBeth Israel Deaconess Medical Center (BIDMC) Institutional Review Board (IRB) Protocol 2020P000323Funding StatementPayments covering the cost of the IRB and clinical trial PCR were provided by Carbon3D, EnvisionTec, and Origin, Inc.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study is available at https://github.com/rarnaout/Covidswab https://github.com/rarnaout/Covidswab